A

s talks wrap up at the United Nations over ways to address a global tuberculosis epidemic, the U.S. has succeeded in removing language from a policy document that patient advocacy groups claim will make access and affordability more difficult for poorer countries.

Specifically, the U.S. has pressed other nations to change language referring to a World Trade Organization agreement that allows countries to issue compulsory licenses as a way to create lower-cost alternatives to medicines, according to the latest version of the agreement reviewed by STAT.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy